Who benefits from adjuvant nivolumab?—real-world outcomes and opportunities for precision risk stratification

Caitlin D. Faust, Varun Nandakumar, Sumati Gupta

Open source

DOI: 10.21037/tau-2026-0997
Published: 2026-10
Container: Translational Andrology and Urology
Publisher: AME Publishing Company
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21037/tau-2026-0997,
  title = {Who benefits from adjuvant nivolumab?—real-world outcomes and opportunities for precision risk stratification},
  author = {Caitlin D. Faust and Varun Nandakumar and Sumati Gupta},
  year = {2026},
  journal = {Translational Andrology and Urology},
  doi = {10.21037/tau-2026-0997},
  url = {https://doi.org/10.21037/tau-2026-0997}
}

RIS

TY  - JOUR
TI  - Who benefits from adjuvant nivolumab?—real-world outcomes and opportunities for precision risk stratification
AU  - Caitlin D. Faust
AU  - Varun Nandakumar
AU  - Sumati Gupta
PY  - 2026
JO  - Translational Andrology and Urology
DO  - 10.21037/tau-2026-0997
UR  - https://doi.org/10.21037/tau-2026-0997
ER  -

APA

Faust, C. D., Nandakumar, V., & Gupta, S. (2026). Who benefits from adjuvant nivolumab?—real-world outcomes and opportunities for precision risk stratification. Translational Andrology and Urology. https://doi.org/10.21037/tau-2026-0997

Source records

crossref · retrieved 2026-11-08T23:17:42.615Z